Debate: Is there an optimal treatment for refractory colorectal cancer? - TAS-102 or regorafenib
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that TAS-102 or regorafenib are the optimal treatment for refractory colorectal cancer.<br /><br />Ear...
Author: imedex
Added: 10/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - EGFR antibodies are mandatory
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR antibodies are mandatory targeted therapy for RAS/BRAF wild-type left sided colon ca...
Author: imedex
Added: 10/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - Either bevacizumab or EGFR antibodies
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-t...
Author: imedex
Added: 10/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017
Although not a year for big advances in colorectal cancer, exciting research with current standards was presented at ESMO 2017. (Source: Medscape Oncology)
Source: Medscape Oncology - October 2, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - No
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the t...
Author: imedex
Added: 09/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2017 Category: Cancer & Oncology Source Type: podcasts
Outreach for colon cancer screening, mutation detection in advanced cancer, vision screening in children, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 05, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - September 5, 2017 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Sidedness of Tumors in Metastatic Colorectal Cancer
Farshid Dayyani, MD, PhD of UC Irvine Health discusses sidedness in colorectal cancer tumors at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Overview of the IDEA Trial in Colorectal Cancer
Farshid Dayyani, MD, PhD of UC Irvine Health gives an overview of the IDEA trial at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Overcoming Resistance to Anti-EGFR Therapy in Patients with Metastatic Colorectal Carcinoma
Farshid Dayyani, MD, PhD of UC Irvine Health discusses the BRAF trial and explains how to overcome resistance to anti-EGFR therapy in patients with metastatic colorectal cancer. This was recorded at t...
Author: moasc
Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO 2017: Promising data on colorectal cancer
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center gives an overview of the most intriguing and most promising clinical data on colorectal cancer presented at the 2017 ASCO Annual Meeting in ...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
The optimal duration of adjuvant chemotherapy in colon cancer
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center explains the optimal duration of adjuvant chemotherapy in colon cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
What have we learned about duration of therapy in the adjuvant CRC setting_
Philip Philip, MD of Karmanos Cancer Institute discusses duration of therapy and whether or not shorter treatments will have the same outcomes for patients with stage III colon cancer. This was record...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
What have we learned about duration of therapy in the adjuvant CRC setting?
Philip Philip, MD of Karmanos Cancer Institute discusses duration of therapy and whether or not shorter treatments will have the same outcomes for patients with stage III colon cancer. This was record...
Author: obr
Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts
Have you adopted vemurafenib in BRAF+ mutated metastatic CRC?
Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: obr
Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts
